425: Quanterix to Acquire Akoya Biosciences, Expanding into Immunology and Oncology

Quanterix Corporation announces its proposed acquisition of Akoya Biosciences, aiming to expand its market reach into immunology and oncology while accelerating growth and profitability.

Summary

• Quanterix Corporation is set to acquire Akoya Biosciences, Inc., pending regulatory and stockholder approvals.
• The acquisition aims to expand Quanterix's reach into immunology and oncology, increasing its total addressable market (TAM) to $5 billion.
• The combined company expects to achieve approximately $220 million in revenue and strong double-digit organic revenue growth by 2026.
• Significant annual cost synergies of around $40 million are anticipated by the end of 2026, with about $20 million expected by the end of the first year post-close.
• The company aims to be cash flow positive in 2026, excluding diagnostics and CDx.
• A combined balance sheet is projected to have $175 million in cash at the time of closing, assuming the deal closes in Q2 2025.
• The merger will create cross-selling opportunities with a combined install base of 2,300 instruments.
• Quanterix is also focused on Alzheimer's disease (AD) diagnostics, with key catalysts expected over the next 12 months.
• The company is building a global infrastructure for AD testing, including partnerships with labs and the development of a multi-marker test (LucentAD Complete).
• Quanterix is investing $20 million to support lab capacity and has a dedicated diagnostics team.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the acquisition of Akoya Biosciences, expected revenue growth, cost synergies, and a path to cash flow positivity. The focus on high-growth markets and advancements in Alzheimer's disease diagnostics further contribute to the positive sentiment.

Positives

• The acquisition of Akoya Biosciences expands Quanterix's market into high-growth areas like immunology and oncology.
• The combined company is expected to achieve significant revenue growth and cost synergies.
• Quanterix is on track to become cash flow positive by 2026.
• The company has a strong balance sheet with a substantial cash position.
• Quanterix is making progress in Alzheimer's disease diagnostics with the development of the LucentAD Complete test.
• The company is expanding its menu of assays and reducing assay development times.
• Quanterix has a growing network of lab partners and is building lab capacity for Alzheimer's disease testing.
• The launch of a new platform at the end of 2025 will enhance sensitivity and expand capabilities.

Negatives

• The preliminary financial information for 2024 is unaudited and subject to adjustment.
• The realization of anticipated benefits and synergies from the Akoya acquisition is subject to risks and uncertainties.
• The proposed transaction may be more expensive to complete than anticipated.
• The integration of the two companies could face challenges.
• The company's share price could be affected before the closing of the proposed transaction.
• The company is reliant on regulatory and stockholder approvals for the acquisition to proceed.

Risks

• The occurrence of any event that could terminate the merger agreement between Quanterix and Akoya.
• Potential legal proceedings against Quanterix or Akoya.
• Failure to obtain necessary regulatory and stockholder approvals.
• The anticipated benefits and synergies of the proposed transaction may not be realized.
• The proposed transaction may be more expensive to complete than anticipated.
• Diversion of management's attention from ongoing business operations.
• Potential adverse reactions or changes to business or employee relationships.
• Changes in Quanterix's share price before the closing of the proposed transaction.
• Risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the proposed transaction.

Future Outlook

The company anticipates strong double-digit organic revenue growth by 2026 and aims to be cash flow positive in 2026, excluding diagnostics and CDx. They also expect significant upside from Alzheimer's diagnostics.

Management Comments

• Masoud Toloue, President and CEO of Quanterix Corporation, delivered a presentation to the employees of Akoya Biosciences, Inc.

Industry Context

The acquisition reflects a trend towards consolidation in the life sciences industry, with companies seeking to expand their product offerings and market reach. The focus on immunology, oncology, and Alzheimer's disease diagnostics aligns with growing demand in these areas.

Comparison to Industry Standards

• Quanterix's SIMOA technology competes with other protein detection methods like ELISA and chemiluminescence, offering higher sensitivity.
• The company's expansion into oncology positions it against companies like Guardant Health and Exact Sciences, which focus on liquid biopsy tests.
• In Alzheimer's disease diagnostics, Quanterix's LucentAD Complete test competes with other multi-marker tests and aims for differentiated reimbursement.
• The company's focus on ultra-sensitive biomarker detection aligns with the industry's move towards early disease detection and personalized medicine.

Stakeholder Impact

• Shareholders of both Quanterix and Akoya Biosciences will be impacted by the acquisition, pending their approval.
• Employees of both companies may experience changes as a result of the integration.
• Customers will benefit from a broader range of products and services.
• The acquisition could impact suppliers and creditors of both companies.

Next Steps

• Obtain necessary regulatory approvals for the acquisition.
• Obtain stockholder approvals for the acquisition.
• Complete the integration of Quanterix and Akoya Biosciences.
• Continue development and commercialization of the LucentAD Complete test for Alzheimer's disease.
• Launch the new platform with enhanced sensitivity at the end of 2025.

Key Dates